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ABSTRACT
Introduction: Infant colic, or excessive crying of
unknown cause in infants less than 3 months old, is
common and burdensome. Its aetiology is
undetermined, and consensus on its management is
still lacking. Recent studies suggest a possible link
between infant colic and gut microbiota, indicating
probiotics to be a promising treatment. However, only
a few strains have been tested, and results from
randomised controlled trials are conflicting. It is
important to clarify whether probiotics are effective for
treating infant colic in general, and to identify whether
certain subgroups of infants with colic would benefit
from particular strains of probiotics.
Methods and analysis: Through an individual
participant data meta-analysis (IPDMA), we aim to
identify whether the probiotic Lactobacillus reuteri
DSM 17938 is effective in the management of infant
colic, and to clarify whether its effects differ according
to feeding method (breast vs formula vs combined),
proton pump inhibitor exposure, and antibiotic
exposure. The primary outcomes are infant crying
duration and treatment success (at least 50% reduction
in crying time from baseline) at 21 days
postintervention. Individual participant data from all
studies will be modelled simultaneously in multilevel
generalised linear mixed-effects regression models to
account for the nesting of participants within studies.
Subgroup analyses of participant-level and
intervention-level characteristics will be undertaken on
the primary outcomes to assess if the intervention
effect differs between certain groups of infants.
Ethics and dissemination: Approved by the Royal
Children’s Hospital Human Research Ethics Committee
(HREC 34081). Results will be reported in a peer-
reviewed journal in 2015.
Trial registration number: PROSPERO
CRD42014013210.
INTRODUCTION
Infant colic, or excessive crying of unknown
cause, is a common, burdensome condition
affecting up to 20% of infants less than
3 months old.1 Although colic self-resolves
beyond the first 3 months of life, it is asso-
ciated with potentially significant adverse
effects, such as maternal depression,2 3 child
abuse,4 5 and early cessation of breast
feeding.6 There is also some evidence of
long-term adverse outcomes, such as behav-
iour and sleep problems.7 8 The aetiology of
infant colic remains unresolved, and effective
treatment options are limited.9–11
Recent research has focused on the role of
gut microbiota in the pathophysiological
Strengths and limitations of this study
▪ This is the first individual participant data
meta-analysis (IPDMA) and the most definitive
method to assess the effectiveness of
Lactobacillus reuteri DSM 17938 in managing
infants with colic, and to clarify which sub-
groups of infants with colic may benefit from
probiotics.
▪ While individual trials can provide important
data, and meta-analyses of randomised con-
trolled trials can give important conclusions,
there can be problems with interpreting such
conclusions. Combining raw data from individual
trials via an IPDMA can yield more reliable esti-
mates of treatment effects with universal applic-
ability. This is particularly important when there
is significant chance that particular strains of
probiotics may work for particular subgroups of
infants with colic, an effect that cannot be
detected by individual studies with limited
sample sizes.
▪ The study is limited by the number of participat-
ing authors who contribute data to the study,
and cannot include data from authors who
decline participation. It is also limited by inclu-
sion of studies with potentially different methods
of defining infant colic and measuring outcomes.
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pathway to infant colic, with numerous studies revealing
differences in gut microbiota between infants with and
without colic.12–21 At the same time, a handful of studies
have examined the role of probiotics—live microorgan-
isms believed to confer a health benefit—in the manage-
ment of infant colic. One study of Lactobacillus reuteri
ATCC 5573022 and two studies of L. reuteri DSM
1793823 24 in breastfed infants with colic were effective,
but a subsequent study of both breastfed and
formula-fed infants with colic indicated L. reuteri DSM
17938 to be ineffective.25 Two other studies using differ-
ent mixtures of probiotic strains were also ineffective in
managing colic.14 26 The reasons for such conflicting evi-
dence are unclear, and there is a need to explore the
reasons behind such controversial results, particularly
with increasing probiotic marketing, variety of strains
used, and addition of probiotics to infant formulae.
Currently, there are some ongoing trials examining the
role of probiotics in managing and preventing infant colic,
using similar designs, participants, interventions, compara-
tors and outcome measures.27 While individual trials can
provide important data, and meta-analyses of randomised
controlled trials can give important conclusions, there can
be problems with interpreting such conclusions.
Ultimately, such meta-analyses often do not overcome lim-
itations and biases of individual trials by generating a
single best estimate through pooling of treatment effect
estimates.28 In contrast, combining raw data from individ-
ual trials via an individual participant data meta-analysis
(IPDMA) can yield more reliable estimates of treatment
effects with universal applicability.28–32 This is particularly
important when there is significant chance that particular
strains of probiotics may work for particular subgroups of
infants with colic, an effect that cannot be detected by
individual studies with limited sample sizes.
The pooling of data into an IPDMA for analysis will
ultimately provide more definitive answers as to whether
the probiotic L. reuteri DSM 17938 is effective for infant
colic, and it will also determine whether certain sub-
groups of infants would benefit from it. As the effects of
probiotics are strain specific,33 this IPDMA will only
include the most commonly studied probiotic strain
used for the management of infant colic, and will form
the protocol basis for further IPDMAs involving other
probiotic strains for the management or prevention of
infant colic.
The aims of this IPDMA are:
1. To determine whether the probiotic L. reuteri DSM
17398 is effective in the management of infant colic;
2. To determine whether the effects of L. reuteri DSM
17398 on infants with colic differ according to
A. Type of feeding (exclusively breast fed vs par-
tially breast fed vs exclusively formula fed);
B. Proton pump inhibitor exposure;
C. Hypoallergenic formula exposure for formula-
fed infants;
D. Maternal dairy elimination diets for breastfed
infants.
METHODS AND ANALYSIS
Search methods for identification of studies
We will search for completed and ongoing randomised
controlled trials by identification of published papers
and protocols through the online databases MEDLINE,
EMBASE, CINAHL, Database of Abstracts of Reviews of
Effects (DARE), Cochrane Central Register for
Controlled Trials (CENTRAL), and clinical trial regis-
tries (eg, metaRegister of Controlled Trials). Reference
lists from articles will be explored to identify other
potential trials. We will also perform internet searches
for non-peer-reviewed articles, media articles and other
relevant publications using Google, and approach pre-
senters at relevant conferences and meetings. This
IPDMA will be undertaken according to the methods
recommended by the Cochrane Collaboration,34 with
reporting following the preferred reporting items for sys-
tematic reviews and meta-analyses (PRISMA)
guidelines.35
Eligibility criteria for included RCTs
The IPDMA will include registered randomised con-
trolled trials of the probiotic L. reuteri DSM 17398 versus
placebo, delivered orally to infants with modified
Wessel’s definition of infant colic (crying for more than
3 h of the day, for more than 3 days of the week, for at
least 1 week, as recorded by diaries, questionnaires or
parental interviews).
Studies evaluating L. reuteri ATCC 55730, the mother
strain of L. reuteri DSM 17938, will be excluded. L. reuteri
ATCC 55730 was found to carry potentially transferable
resistance traits for tetracycline and lincomycin. Hence,
it was replaced by L. reuteri DSM 17938, a strain without
unwanted plasmid-borne resistance.36 It remains a
matter of debate whether or not L. reuteri DSM 17938,
the strain with antibiotic resistance plasmids removed,
and the original L. reuteri ATCC 55730 strain can be
regarded as equal. Moreover, only L. reuteri DSM 17938
is commercially available.
All authors of eligible trials have been contacted and
invited to participate in this IPDMA. As more trials satis-
fying eligibility criteria get published, the relevant
authors will be approached and invited to participate, as
long as their trials are published within the time frame
of conducting this IPDMA.
Main outcomes
The primary outcomes of the IPDMA are:
▸ Infant crying duration (minutes per day) at 21 days
postintervention;
▸ Treatment success at 21 days postintervention,
defined as at least 50% reduction in crying time from
baseline.
Secondary outcomes include:
▸ Infant crying duration (minutes per day) at days 7, 14
and 28 postintervention;
▸ Treatment success (at least 50% reduction in crying
time) at days 7, 14 and 28 postintervention;
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▸ Infant sleep duration (minutes per day) per 24 h at
7, 14, 21 and 28 days duration (post-treatment
baseline);
▸ Parental report of treatment success, maternal depres-
sion, quality of life, and family functioning at the end
of the intervention period;
▸ Adverse effects: diarrhoea, constipation, vomiting,
apnoea and apparent life-threatening events (ALTE);
▸ Stool colonisation analysis;
▸ Faecal calprotectin levels.
We anticipate that not all included studies will have all
secondary outcomes available for analysis, and will
analyse only data that are available.
Sample size and power calculation
Abstracting data from published randomised trials, esti-
mates of the SDs in crying time (min/day) at baseline
and day 21 were collected and pooled to provide an esti-
mated SD of 210 (min/day). From this information, it is
estimated that approximately 120 infants per treatment
group would be sufficient for detecting a mean differ-
ence in treatment groups of 80 min/day (power=0.80,
α=0.05, two-tailed). Additionally, approximately 120 per
group would also provide 80% power for detecting a dif-
ference of 20 percentage points (α=0.05, two-tailed) in
the treatment success rates. Treatment success is defined
as (yes/no) with ‘yes’ corresponding to at least 50%
reduction in crying time from baseline to day 21.
For subgroup analysis to compare whether treatment
effects differed by patient characteristics, hypothesis
testing will be based on the comparison of treatment
effects between subgroups, with a two-tailed α of 0.10
used to offset the decreased precision available for esti-
mating interaction effects (ie, differences in differ-
ences). We specified that it would be clinically
significant to detect between-subgroup differences in
treatment effects of 150 min/day on the crying time
outcome and of 50 percentage points on the treatment
success outcome, assuming that one subgroup consists
of between 33% and 66% of the full sample and the
other subgroup consists of the remainder. For example,
if treatment group differences truly are 180 min/day in
a prespecified subgroup with one-third of the patients
and only 30 min/day for the remaining patients, the dif-
ference in treatment effects would correspond to
150 min/day. Again, a sample size of approximately 120
infants provides at least 80% power to detect such clinic-
ally important differences.
At the time of this writing, authors of four trials have
agreed to participate. These four trials include three
that assessed L. reuteri strain DSM 17398, comprising a
total of 293 patients with 150 randomised to probiotic
and 143 to placebo. Thus, it is projected that this
IPDMA will have sufficient power for detecting clinically
relevant differences in both the average crying times
and success rates of at least 50% reduction from baseline
to day 21 between the probiotic and placebo groups.
Statistical analysis
The analysis will be conducted with individual partici-
pant data from all studies modelled simultaneously in
multilevel generalised linear mixed-effects regression
models to account for the nesting of participants within
studies.29 Models will be specified with fixed-effects
terms for the individual participant’s binary indicator
treatment-assignment (probiotic vs control), a parsimo-
nious set of prespecified participant-level characteristics,
and the study identifier. This model specification will be
straightforwardly extended to account for when longitu-
dinally assessed outcomes are the units of analysis (one
record per time point per participant), by including
fixed-effects terms for time (main effects as well as inter-
action terms with the binary treatment indicator) and
random effects for the participant to account for
residual within-participant correlation. Standard choices
of link and variance functions will be specified, accord-
ing to type of outcome, with linear-normal models used
for suitably (ie, homogeneous) continuous outcomes
and logit-binomial and log-Poisson models used for
binary and count outcomes, respectively.
Subgroup analyses of participant-level and
intervention-level characteristics will be undertaken on
the primary outcomes to assess if the intervention
effect differs between certain groups of infants.
Heterogeneity of treatment effects will be formally
assessed by respecifying regression models with inter-
action terms for the binary treatment indicator with
the candidate-effect modifier and conducting formal
hypothesis testing (with a statistical significance thresh-
old reset to 0.10 to help offset the low statistical power
associated with testing interaction terms). These
characteristics are identified a priori and include: (1)
feeding method (exclusively breast fed vs partially
breast fed vs exclusively formula fed), (2) proton pump
inhibitor exposure, (3) hypoallergenic formula expos-
ure for formula-fed infants and (4) maternal dairy
elimination diets for breast-fed infants. Confounders
identified a priori will include (1) family history of
atopy, (2) delivery type (vaginal vs caesarean), (3)
enrolment age and (4) antibiotic use.
Analysis will be by intention-to-treat; specifically, the
binary treatment term will correspond to assigned treat-
ment. Missing data patterns and assumptions will be
described, and the potential impact of alternative
missing data assumptions on the primary analysis will be
explored in sensitivity analyses. The primary analysis will
be conducted at the 0.05 level of significance.
ETHICS AND DISSEMINATION
Ethics committee approval
The IPDMA has been approved by the Royal Children’s
Hospital Human Research Ethics Committee (HREC
34081). The IPDMA is registered at PROSPERO, the
International Prospective Register of Systematic Reviews,
at the University of York (CRD42014013210).
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Project management and data collection
Membership to the collaboration for this IPDMA will
include representatives from each trial contributing data
to the project, a project coordination team, and a data
management team consisting of two independent statisti-
cians (FDA and DT). The collaboration will collect the
minimum de-identified data required to answer the
research questions. We will store data in a secure, centra-
lised, customised database, accessible only by a unique
passcode known only to the project coordination team,
data management team, and managers of each individ-
ual study contributing data. The two independent statis-
ticians will inspect the data with respect to range,
internal consistency, and missing items by checking
them against published reports, trial protocols and, if
necessary, data collection sheets. The statisticians will
discuss any inconsistencies or missing data with individ-
ual trial managers, and any problems will be resolved by
consensus using original raw data.
Data ownership and confidentiality
All included trials must have been given ethical approval
by their respective HREC. Participants in individual
trials must have consented to their participation in their
respective trial. Each study manager remains the custo-
dian of their own data and retains the right to withdraw
their data from the analysis at any time. Data must be
de-identified before being shared for this IPDMA. The
pooled data can be accessed by the project coordination
team, data management team, and managers of each
individual study contributing data. The project intellec-
tual property (IP) will be owned by the parties as
tenants in common in proportion to their respective
contributions to that project IP (including, without limi-
tation, contributions and inventorship).
Data monitoring procedures
Each individual trial will follow its own data monitoring
procedures. The collaboration plans to update the
IPDMA data at regular intervals if further relevant indi-
vidual trials are completed with available data.
Risks and benefits
The main risk for this study is the discovery of discrepant
data, or results that are inconsistent with published
manuscripts; however, all the studies have been pub-
lished in peer-reviewed, scientific journals. In addition,
this risk will be minimised by careful handling of the
data, involvement of two independent statisticians in
data analysis, having a unified plan for management of
missing data, and the plan for open discussions to
resolve any issues regarding any conflicting information.
Participation in this study requires prior consent and
approval of all trial managers in sharing each study’s
data and subjecting individual data to reanalysis. There
is also a risk of inadequate representation of all trial par-
ticipants due to authors who do not consent to their
data being pooled into the IPDMA.
The combination of data from multiple, similar trials
via an IPDMA can yield more reliable estimates of treat-
ment effects, especially for small subgroups of
patients.29–32 The patients enrolled in each of the indi-
vidual studies may have had particular patient character-
istics or exposures that may have affected the
effectiveness of the probiotic intervention. In addition,
the different studies may have varied in the types of
patients they recruited or varied slightly in their recruit-
ment criteria. As a result, in addition to making more
definitive conclusions as to whether probiotics are effect-
ive for infant colic, this IPDMA will be able to help
determine if there are subgroups of infants who might
benefit from a probiotic intervention for colic, in
general, or to a particular probiotic strain.
Publication plan
Each individual trial will have the right to publish its
main results before publication of this IPDMA. Study
results from this meta-analysis will be reported in a peer-
reviewed journal in 2015. Before publication of any
IPDMA manuscripts, drafts will be circulated for
comment, revision and approval by a nominated repre-
sentative of each of the participating trials. Publications
using these data will be authored on behalf of the
IPDMA collaboration, with specific named authors
(including a representative of each participating trial,
the project coordination team and data management
team) according to the amount of contribution to each
manuscript, and names of other participating collabora-
tors listed in the Acknowledgements.
STRENGTHS AND LIMITATIONS OF THE STUDY
This is the first IPDMA and the most definitive method
to assess the effectiveness of L. reuteri DSM 17938 in
managing infants with colic, and to clarify which sub-
groups of infants with colic may benefit from probiotics.
The study is limited by the number of participating
authors who contribute data to the study, and cannot
include data from authors who decline participation.
The study is also limited by inclusion of studies with dif-
fering methods of defining infant colic and measuring
outcomes. The collaboration formed through this
IPDMA will be the platform to conduct future IPDMAs
for the probiotic management and prevention of infant
colic.
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